Unlike established (or emerging) markers of malignant parathyroid disease, such as CDC73 mutations and loss of parafibromin expression, hCG represents a non-invasive (rapidly available) and practical biomarker, particularly when there is diagnostic uncertainty or biopsy and surgical resection are delayed. Here, CDC73 is linked to parathyroid gland disorder.